SG
UTHR icon

Societe Generale’s United Therapeutics UTHR Stock Holding History

Societe Generale’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.41M Buy
+13,297
New +$1.48M 0.01% 1074

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Societe Generale's UTHR Position: Q2 2016 in Review

Societe Generale opened a new position in United Therapeutics (UTHR) in Q2 2016: 13,297 shares worth $1.41M. The stake represents 0.01% of the portfolio and ranks #1074 among its holdings.

384 funds tracked by Wall St. Rank hold UTHR as of Q2 2016.

  • Societe Generale held 13,297 shares of United Therapeutics worth $1.41M as of Q2 2016.
  • United Therapeutics was a new Societe Generale position in Q2 2016.
  • United Therapeutics made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1074 holding.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.